Pub Date : 2021-05-01DOI: 10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1995
G. Senyei, D. Nettlow, M. Nobari, R. Miller, G. Cheng
Introduction: Life-threatening hemoptysis is rare in patients diagnosed with COVID-19. Here, we describe a severe case of hemoptysis a patient with COVID-19 and the multi-modal approach to manage this condition. Case: A 57 year-old man with diabetes was admitted with hypoxemic respiratory failure due to COVID-19 pneumonia. Despite treatment with convalescent plasma, remdesivir and dexamethasone, he developed progressive respiratory failure eventually requiring VVECMO support on hospital day 8. He was started on heparin for therapeutic anticoagulation at this time. Anticoagulation was held on day 23 after large blood clots were suctioned via tracheostomy tube. CT revealed complete opacification of the bilateral lungs and major airways without evidence of acute arterial blushing (panel A). The patient underwent the first in a series of therapeutic bronchoscopies via a size 10 Shiley tracheostomy tube on day 28. Occlusive gelatinous blood clots were noted immediately upon entering the trachea. After failure of adequate clot evaluation with cryoprobe, a modified 24F chest tube was used as a suction catheter to achieve clot removal. After visualizing major airways, a bronchial blocker was positioned in the bronchus intermedius. Topical tranexamic acid was applied to sites of bleeding in the left upper lobe. Repeat bronchoscopy was performed on day 30, which showed new bleeding in the left lower lobe segments. An endobronchial blocker was repositioned in the left lower lobe and Surgicel was applied to ongoing bleeding sites within the right and left lung. Prior to repeat bronchoscopy, the patient was administered inhaled tranexamic acid three times daily due to findings of severely inflamed mucosa and diffused nature of bleed. On day 32, bronchoscopy revealed significantly improved bleeding. In-line suctioning was held in favor of daily diagnostic bronchoscopies to avoid suction trauma. Ultimately, the patient's bleeding resolved and he was eventually liberated from both ECMO and the ventilator with corresponding improvement on CT imaging (panel B). Discussion: We describe a case of a life-threatening hemoptysis in a patient with COVID-19 ARDS who was successfully managed using serial therapeutic bronchoscopies employing cryotherapy, mechanical tamponade, and pharamacologic coagulants to achieve hemostasis.
{"title":"A Multi-Modal Approach to Life-Threatening Hemoptysis in a Patient with COVID-19 ARDS","authors":"G. Senyei, D. Nettlow, M. Nobari, R. Miller, G. Cheng","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1995","DOIUrl":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1995","url":null,"abstract":"Introduction: Life-threatening hemoptysis is rare in patients diagnosed with COVID-19. Here, we describe a severe case of hemoptysis a patient with COVID-19 and the multi-modal approach to manage this condition. Case: A 57 year-old man with diabetes was admitted with hypoxemic respiratory failure due to COVID-19 pneumonia. Despite treatment with convalescent plasma, remdesivir and dexamethasone, he developed progressive respiratory failure eventually requiring VVECMO support on hospital day 8. He was started on heparin for therapeutic anticoagulation at this time. Anticoagulation was held on day 23 after large blood clots were suctioned via tracheostomy tube. CT revealed complete opacification of the bilateral lungs and major airways without evidence of acute arterial blushing (panel A). The patient underwent the first in a series of therapeutic bronchoscopies via a size 10 Shiley tracheostomy tube on day 28. Occlusive gelatinous blood clots were noted immediately upon entering the trachea. After failure of adequate clot evaluation with cryoprobe, a modified 24F chest tube was used as a suction catheter to achieve clot removal. After visualizing major airways, a bronchial blocker was positioned in the bronchus intermedius. Topical tranexamic acid was applied to sites of bleeding in the left upper lobe. Repeat bronchoscopy was performed on day 30, which showed new bleeding in the left lower lobe segments. An endobronchial blocker was repositioned in the left lower lobe and Surgicel was applied to ongoing bleeding sites within the right and left lung. Prior to repeat bronchoscopy, the patient was administered inhaled tranexamic acid three times daily due to findings of severely inflamed mucosa and diffused nature of bleed. On day 32, bronchoscopy revealed significantly improved bleeding. In-line suctioning was held in favor of daily diagnostic bronchoscopies to avoid suction trauma. Ultimately, the patient's bleeding resolved and he was eventually liberated from both ECMO and the ventilator with corresponding improvement on CT imaging (panel B). Discussion: We describe a case of a life-threatening hemoptysis in a patient with COVID-19 ARDS who was successfully managed using serial therapeutic bronchoscopies employing cryotherapy, mechanical tamponade, and pharamacologic coagulants to achieve hemostasis.","PeriodicalId":23189,"journal":{"name":"TP31. TP031 INTERESTING CASES ASSOCIATED WITH SARS-COV-2 INFECTION","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81253388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-01DOI: 10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1993
S. Golob, L. Winston, D. Manson, S. Fedyna
Introduction: Electronic-cigarette or vaping-product associated lung injury (EVALI) was first identified in August 2019, when U.S. public health officials noted a clinical syndrome of acute respiratory failure and systemic inflammation associated with the use of aerosolized nicotine and cannabinoids. The presence of lipid-laden macrophages on bronchiolar lavage is a specific but not sensitive histological finding of EVALI, which is often a diagnosis of exclusion. In 2020, the first cases of COVID-19, caused by SARS-CoV2 virus, were seen in the U.S. Both COVID-19 and EVALI can affect previously healthy individuals, manifesting with severe hypoxemia and systemic inflammation, posing diagnostic challenges in distinguishing the two syndromes. Secondary spontaneous pneumothorax is a well-described complication of COVID-19 yet is only rarely associated with EVALI, with only one published case report of EVALI complicated by pneumothorax. Here, we report a case of a 34-year-old man presenting with hypoxemic respiratory failure complicated by pneumothorax, initially thought to be from COVID-19 pneumonia, found ultimately to have EVALI associated diffuse alveolar damage. Case: In April 2020, a 34-year-old man presented with one week of myalgia, shortness of breath, and a reduced exercise tolerance. Social history was notable for extensive vaping. His exam was notable for hypoxemia requiring nonrebreather. Testing showed elevated inflammatory markers and diffuse bilateral opacities on chest radiography. Nasopharyngeal PCR was negative for SARS-CoV2. CT chest revealed dense consolidation with ground grass opacities and air bronchograms. Rheumatologic and infectious workup was unremarkable. Despite six negative SARS-CoV2 tests, he was treated for COVID-19 with empiric steroids and antibiotics for community-acquired pneumonia. On hospital day 3, he developed a right-sided pneumothorax requiring chest tube. On hospital day 12, he developed a left-sided pneumothorax and a second chest tube was placed. A presumptive diagnosis of pneumonitis and diffuse alveolar damage secondary to EVALI was made. Given non-healing bilateral pneumothoraces, on hospital day 32, he underwent chemical pleurodesis with doxycycline which was complicated by ARDS. He was intubated, suffered a PEA arrest from refractory hypoxemia, and emergently cannulated to VV ECMO. A head CT demonstrated diffuse cerebral edema suggestive of anoxic brain injury. After extensive goals of care discussions, care was withdrawn and the patient passed away. Discussion: EVALI, similar to COVID-19, is syndrome of severe acute hypoxemia and systemic inflammation. Both conditions have similar radiographic findings with ground glass opacities indicative of alveolar damage, histological findings of tracheobronchitis and diffuse alveolar damage, and can lead to secondary spontaneous pneumothoraces.
{"title":"E-Cigarette or Vaping-Product Associated Lung Injury Complicated by Spontaneous Pneumothoraces in the Setting of COVID-19 Pandemic","authors":"S. Golob, L. Winston, D. Manson, S. Fedyna","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1993","DOIUrl":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1993","url":null,"abstract":"Introduction: Electronic-cigarette or vaping-product associated lung injury (EVALI) was first identified in August 2019, when U.S. public health officials noted a clinical syndrome of acute respiratory failure and systemic inflammation associated with the use of aerosolized nicotine and cannabinoids. The presence of lipid-laden macrophages on bronchiolar lavage is a specific but not sensitive histological finding of EVALI, which is often a diagnosis of exclusion. In 2020, the first cases of COVID-19, caused by SARS-CoV2 virus, were seen in the U.S. Both COVID-19 and EVALI can affect previously healthy individuals, manifesting with severe hypoxemia and systemic inflammation, posing diagnostic challenges in distinguishing the two syndromes. Secondary spontaneous pneumothorax is a well-described complication of COVID-19 yet is only rarely associated with EVALI, with only one published case report of EVALI complicated by pneumothorax. Here, we report a case of a 34-year-old man presenting with hypoxemic respiratory failure complicated by pneumothorax, initially thought to be from COVID-19 pneumonia, found ultimately to have EVALI associated diffuse alveolar damage. Case: In April 2020, a 34-year-old man presented with one week of myalgia, shortness of breath, and a reduced exercise tolerance. Social history was notable for extensive vaping. His exam was notable for hypoxemia requiring nonrebreather. Testing showed elevated inflammatory markers and diffuse bilateral opacities on chest radiography. Nasopharyngeal PCR was negative for SARS-CoV2. CT chest revealed dense consolidation with ground grass opacities and air bronchograms. Rheumatologic and infectious workup was unremarkable. Despite six negative SARS-CoV2 tests, he was treated for COVID-19 with empiric steroids and antibiotics for community-acquired pneumonia. On hospital day 3, he developed a right-sided pneumothorax requiring chest tube. On hospital day 12, he developed a left-sided pneumothorax and a second chest tube was placed. A presumptive diagnosis of pneumonitis and diffuse alveolar damage secondary to EVALI was made. Given non-healing bilateral pneumothoraces, on hospital day 32, he underwent chemical pleurodesis with doxycycline which was complicated by ARDS. He was intubated, suffered a PEA arrest from refractory hypoxemia, and emergently cannulated to VV ECMO. A head CT demonstrated diffuse cerebral edema suggestive of anoxic brain injury. After extensive goals of care discussions, care was withdrawn and the patient passed away. Discussion: EVALI, similar to COVID-19, is syndrome of severe acute hypoxemia and systemic inflammation. Both conditions have similar radiographic findings with ground glass opacities indicative of alveolar damage, histological findings of tracheobronchitis and diffuse alveolar damage, and can lead to secondary spontaneous pneumothoraces.","PeriodicalId":23189,"journal":{"name":"TP31. TP031 INTERESTING CASES ASSOCIATED WITH SARS-COV-2 INFECTION","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74575052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-01DOI: 10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2009
J. Kirupakaran, D. Valentine, A. Idowu, M. Jiménez, M. Okaikoi, A. M. Thida, G. Bahtiyar, G. Aristide, G. Rodriguez
INTRODUCTION Coronavirus-19 disease (COVID-19) caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to be a major cause of mortality worldwide. Advanced age and a number of chronic diseases have been investigated as risk factors for poor outcomes in patients with COVID-19. Likewise, Human Immunodeficiency Virus (HIV) has been proposed as a potential risk factor for COVID-19, however, the possible relationship between HIV and COVID-19 has remained difficult to fully elucidate due to a paucity of data. We describe a case series of 11 patients co-infected with HIV and SARS-CoV-2. CASE PRESENTATION Between March 20, 2020 and May 5, 2020, 11 patients with HIV were admitted for COVID-19at an underserved community hospital in Brooklyn, NY. . Patients ranged from 39 to 78 years of age. Seven patients were men and four patients were women. Seven patients were African American and four patients were Hispanic. All 11 patients possessed HIV RNA viral loads less than 40 copies/ml. The mean CD4 count was 556 cells/ml (range 171-1123 cells/ml). Nine patients were on antiretroviral therapy (ART). Six patients required invasive mechanical ventilation;five of the six patients died. Two of these five patients were not on ART, prior to admission and two of them developed acute respiratory distress syndrome during their hospital course. The mean length of stay was 10.9 days (range 2-21 days). Three of the six survivors were readmitted within 30 days for CHF exacerbation, bacterial pneumonia and COPD exacerbation. All three patients recovered without complications. At six-month follow-up, no mortalities were reported among the six surviving patients. DISCUSSION This case series presents a unique sample of African American and Hispanic patients co-infected with HIV and SARS-CoV-2. This is the first case series to report long term outcomes among minority population. The high mortality rate in this case series (45%) is also notable in comparison to prior research. This elevated mortality rate may reflect an increased burden of comorbidities in HIV patients. Further research is required to reveal if ART therapy reduces risk of poor outcomes, and if so, which regimen may confer protection against COVID-19.
{"title":"Clinical Features and Outcomes of Hospitalized Patients Co-Infected with COVID-19 and HIV: A Case Series","authors":"J. Kirupakaran, D. Valentine, A. Idowu, M. Jiménez, M. Okaikoi, A. M. Thida, G. Bahtiyar, G. Aristide, G. Rodriguez","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2009","DOIUrl":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2009","url":null,"abstract":"INTRODUCTION Coronavirus-19 disease (COVID-19) caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to be a major cause of mortality worldwide. Advanced age and a number of chronic diseases have been investigated as risk factors for poor outcomes in patients with COVID-19. Likewise, Human Immunodeficiency Virus (HIV) has been proposed as a potential risk factor for COVID-19, however, the possible relationship between HIV and COVID-19 has remained difficult to fully elucidate due to a paucity of data. We describe a case series of 11 patients co-infected with HIV and SARS-CoV-2. CASE PRESENTATION Between March 20, 2020 and May 5, 2020, 11 patients with HIV were admitted for COVID-19at an underserved community hospital in Brooklyn, NY. . Patients ranged from 39 to 78 years of age. Seven patients were men and four patients were women. Seven patients were African American and four patients were Hispanic. All 11 patients possessed HIV RNA viral loads less than 40 copies/ml. The mean CD4 count was 556 cells/ml (range 171-1123 cells/ml). Nine patients were on antiretroviral therapy (ART). Six patients required invasive mechanical ventilation;five of the six patients died. Two of these five patients were not on ART, prior to admission and two of them developed acute respiratory distress syndrome during their hospital course. The mean length of stay was 10.9 days (range 2-21 days). Three of the six survivors were readmitted within 30 days for CHF exacerbation, bacterial pneumonia and COPD exacerbation. All three patients recovered without complications. At six-month follow-up, no mortalities were reported among the six surviving patients. DISCUSSION This case series presents a unique sample of African American and Hispanic patients co-infected with HIV and SARS-CoV-2. This is the first case series to report long term outcomes among minority population. The high mortality rate in this case series (45%) is also notable in comparison to prior research. This elevated mortality rate may reflect an increased burden of comorbidities in HIV patients. Further research is required to reveal if ART therapy reduces risk of poor outcomes, and if so, which regimen may confer protection against COVID-19.","PeriodicalId":23189,"journal":{"name":"TP31. TP031 INTERESTING CASES ASSOCIATED WITH SARS-COV-2 INFECTION","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86707232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-01DOI: 10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1986
Lisa N Glass, Pulmonary Disease, Sandrine Hanna, John P Lichtenberger, Ivana Milojevic, J. Ahari
Organizing pneumonia is a process of lung parenchymal injury caused by multiple etiologies. Although organizing pneumonia may be an idiopathic process, it usually occurs secondary to infection, aspiration, autoimmune disease, and after organ transplantation or radiation. We present a case of organizing pneumona after confirmed SARS-CoV-2 (COVID-19) infection manifesting as chronic cough. Keywords: Organizing pneumonia; COVID-19; Post-viral syndrome; Chronic cough.
{"title":"A Continuous Cough After COVID-19","authors":"Lisa N Glass, Pulmonary Disease, Sandrine Hanna, John P Lichtenberger, Ivana Milojevic, J. Ahari","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1986","DOIUrl":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1986","url":null,"abstract":"Organizing pneumonia is a process of lung parenchymal injury caused by multiple etiologies. Although organizing pneumonia may be an idiopathic process, it usually occurs secondary to infection, aspiration, autoimmune disease, and after organ transplantation or radiation. We present a case of organizing pneumona after confirmed SARS-CoV-2 (COVID-19) infection manifesting as chronic cough. Keywords: Organizing pneumonia; COVID-19; Post-viral syndrome; Chronic cough.","PeriodicalId":23189,"journal":{"name":"TP31. TP031 INTERESTING CASES ASSOCIATED WITH SARS-COV-2 INFECTION","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79019275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-01DOI: 10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2000
G. C. Chiang, T. Zaman, P. Noble
A 79-year-old male presented for evaluation of dyspnea and dry cough. Five months prior he was hospitalized with COVID-19 and a pulmonary embolus requiring 2L/min of supplemental oxygen, enoxaparin, hydroxychloroquine and remdesivir. He was discharged home with apixaban and supplemental oxygen. He had a 10 pack-per-year history of smoking and quit fifty years ago. He had no occupational or environmental exposures associated with pulmonary fibrosis. He had no family history of connective tissue disease or pulmonary fibrosis. On physical examination, he had normal vital signs and his saturation was 100% on room air. Pertinent positive exam findings were limited to bibasilar dry crackles. There were no skin, joint, or oral findings. Pulmonary function tests showed normal lung volumes with normal spirometry and a severely decreased diffusing capacity. A CT revealed improvement of ground glass opacities with persistent subpleural reticulations and honeycombing. Notably, lung images of the lower lobes from a CT scan of the abdomen six years prior to this evaluation showed bibasilar reticulations and ground glass infiltrates. Laboratory studies were notable for an elevated ANA titer in a speckled pattern, elevated CCP and elevated anti-SSA 52 kD. Additional autoimmune serologies were negative. Given the presence of interstitial lung abnormalities (ILAs) in prior imaging and elevated autoimmune markers, he was deemed to have had an exacerbation of previously subclinical ILD caused by COVID-19. The long-term effects of the inflammatory response from COVID-19 have not been characterized. Initial data of CT scans in patients show that up to 17% develop fibrotic changes during the course of the disease. It remains to be seen whether there will be a progressive fibrotic phenotype solely attributable COVID-19 itself. This has been described during the H1N1 and SARS-COV1 outbreaks in patients who developed ARDS but is not observed in post-ARDS pulmonary fibrosis caused by other etiologies. The key to differentiating between a primary ILD rather than post-COVID-19 hinges on antecedent history. The patient's prior radiographic findings meet the research construct of interstitial lung abnormalities (ILA) which refers to patterns of increased lung density in patients with no history of ILD. When post-COVID-19 pulmonary fibrosis is observed, due diligence must be taken to determine alternate etiologies of subclinical ILD that may have been unmasked by COVID-19, rather than caused by it. It remains unclear whether SARS-CoV-2 could activate a latent autoimmunity or potentially cause a de novo autoimmune lung disease as has been suggested.
{"title":"The Chicken or the Egg? Newly Diagnosed Interstitial Lung Disease (ILD) After Novel Coronavirus Pneumonia (COVID-19)","authors":"G. C. Chiang, T. Zaman, P. Noble","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2000","DOIUrl":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2000","url":null,"abstract":"A 79-year-old male presented for evaluation of dyspnea and dry cough. Five months prior he was hospitalized with COVID-19 and a pulmonary embolus requiring 2L/min of supplemental oxygen, enoxaparin, hydroxychloroquine and remdesivir. He was discharged home with apixaban and supplemental oxygen. He had a 10 pack-per-year history of smoking and quit fifty years ago. He had no occupational or environmental exposures associated with pulmonary fibrosis. He had no family history of connective tissue disease or pulmonary fibrosis. On physical examination, he had normal vital signs and his saturation was 100% on room air. Pertinent positive exam findings were limited to bibasilar dry crackles. There were no skin, joint, or oral findings. Pulmonary function tests showed normal lung volumes with normal spirometry and a severely decreased diffusing capacity. A CT revealed improvement of ground glass opacities with persistent subpleural reticulations and honeycombing. Notably, lung images of the lower lobes from a CT scan of the abdomen six years prior to this evaluation showed bibasilar reticulations and ground glass infiltrates. Laboratory studies were notable for an elevated ANA titer in a speckled pattern, elevated CCP and elevated anti-SSA 52 kD. Additional autoimmune serologies were negative. Given the presence of interstitial lung abnormalities (ILAs) in prior imaging and elevated autoimmune markers, he was deemed to have had an exacerbation of previously subclinical ILD caused by COVID-19. The long-term effects of the inflammatory response from COVID-19 have not been characterized. Initial data of CT scans in patients show that up to 17% develop fibrotic changes during the course of the disease. It remains to be seen whether there will be a progressive fibrotic phenotype solely attributable COVID-19 itself. This has been described during the H1N1 and SARS-COV1 outbreaks in patients who developed ARDS but is not observed in post-ARDS pulmonary fibrosis caused by other etiologies. The key to differentiating between a primary ILD rather than post-COVID-19 hinges on antecedent history. The patient's prior radiographic findings meet the research construct of interstitial lung abnormalities (ILA) which refers to patterns of increased lung density in patients with no history of ILD. When post-COVID-19 pulmonary fibrosis is observed, due diligence must be taken to determine alternate etiologies of subclinical ILD that may have been unmasked by COVID-19, rather than caused by it. It remains unclear whether SARS-CoV-2 could activate a latent autoimmunity or potentially cause a de novo autoimmune lung disease as has been suggested.","PeriodicalId":23189,"journal":{"name":"TP31. TP031 INTERESTING CASES ASSOCIATED WITH SARS-COV-2 INFECTION","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84284136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：